NCT06480578RecruitingPhase 2
An Integrated Intervention Using a Pill Ingestible Sensor System
An Integrated Intervention Using a Pill Ingestible Sensor System to Trigger Actions on Multifaceted Social and Behavioral Determinants of Health Among PLWH
Source: ClinicalTrials.gov · Last updated 13 Feb 2026
Brief summary (registry, in English)
This study integrates technology-based adherence measures with alerts for social and behavioral determinants of health (SBDOH) to improve HIV treatment outcomes. It involves 110 adult patients from a Los Angeles County HIV clinic, focusing on those at risk for poor adherence. Participants will be randomized into intervention or usual care groups, with endpoints including intervention acceptability, SBDOH interventions, adherence to ART, viral load, and high-risk sexual activity. The study aims to assess the effectiveness of the integrated intervention in improving adherence, virologic outcomes, and reducing high-risk behavior among PLWH.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 110 (estimated)
- First submitted
- 15 Mar 2024
- Start date
- 19 Dec 2024
- Primary completion date
- 1 Jul 2027
- Lead sponsor
- University of California, Los Angeles
- Diseases
- HIV
- NCT number
- NCT06480578
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 110
- From 19 Dec 2024 to the primary completion date, 1 Jul 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study design.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Inability to follow the study procedures manifested during the intake, as evidenced by mental confusion, disorganization, intoxication, withdrawal, risky or threatening behavior
- Pregnancy (Evaluated during the screening visit through a pregnancy test.)
Who the study is looking for
- HIV-infected individuals in HIV care
- Greater than 17 years of age
- Demonstrated ability to take co-encapsulated ARVs at the time of screening
- Able to provide informed consent
- Receiving ART with sub-optimal adherence estimated by patient (self-reports \< 90% adherence over last 28 days) or treating clinician \[e.g., based on gaps in treatment (e.g. missed appointments) or viral load elevations within 6 months\], or at high risk for sub-optimal adherence, or with known challenges with SBDOH (e.g. unstable housing, substance use disorder, and poverty
- Currently receiving antiretroviral treatment that includes one of the following:
- TDF/FTC (Truvada)
- TAF/FTC (Descovy)
- EFV/FTC/TDF (Atripla)
- ABC/3TC (Epzicom)
- DTG/ABC/3TC (Triumeq)
- RPV/TAF/FTC (Odefsey)
- EVG/c/FTC/TAF (Genvoya)
- BIC/FTC/TAF (Biktarvy)
- For participants of reproductive potential, negative serum or urine pregnancy test with a sensitivity of ≤25 mIU/mL at screening. This will be repeated again at study entry.
- NOTE: Participants are considered to be NOT of reproductive potential if:
- participants have had amenorrhea for at least 12 consecutive months prior to study entry (i.e., who have had no menses within 12 months prior to study entry), and have a documented FSH \>40 IU/mL; OR
- an FSH level is not available, but participants have had 24 consecutive months of amenorrhea (in the absence of medications known to induce amenorrhea); OR
- participants report having undergone surgical sterilization (e.g., hysterectomy, or bilateral oophorectomy, or bilateral tubal ligation/hysteroscopic tubal occlusion).
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Lundquist Coordinator of this site? Confirm its status | Los Angeles | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.